(S)-7-(3-methoxyphenyl)-3-(6-[tetrahydrofuran-3-yl]oxymethylpyrid-2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine | 1202402-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (S)-7-(3-methoxyphenyl)-3-(6-[tetrahydrofuran-3-yl]oxymethylpyrid-2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
• 英文别名: 7-(3-methoxyphenyl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine
• CAS: 1202402-99-0
• 化学式: C₂₂H₂₃N₇O₃
• 分子量: 433.47
• InChiKey: WWQICUBFUVNADI-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  7-chloro-3-{6-[(S)-(tetrahydrofuran-3-yl)oxymethyl]pyridin-2-ylmethyl}-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamine 、 3-甲氧基苯硼酸 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.5h， 以43%的产率得到(S)-7-(3-methoxyphenyl)-3-(6-[tetrahydrofuran-3-yl]oxymethylpyrid-2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine
  参考文献：
  名称：

  [EN] TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE TRIAZALO [4, 5-D] PYRAMIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS DE LA PURINE

  摘要：

  具有化学式（I）的化合物，能够作为嘌呤受体拮抗剂的药物组合物，以及制备这些化合物的方法已被披露。这些化合物和组合物可用于治疗或预防与嘌呤受体过度功能有关的疾病。

  公开号：

  WO2009156737A1

文献信息

• TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
  申请人：Bamford Samantha Jane

  公开号：US20110172252A1

  公开（公告）日：2011-07-14

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  公开了化学式为（I）的化合物，这些化合物能够作为嘌呤受体拮抗剂，包括这些化合物的制药组合物，以及制备这些化合物的方法。这些化合物和组合物可用于治疗或预防与嘌呤受体过度功能有关的疾病。
• TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
  申请人：Vernalis Research Limited

  公开号：US20130245044A1

  公开（公告）日：2013-09-19

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  本文披露了化学式（I）的化合物，这些化合物能够作为嘌呤受体拮抗剂，制备了这些化合物的方法和制药组合物。这些化合物和组合物可用于治疗或预防与嘌呤受体过度功能相关的疾病。
• TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
  申请人：Vernalis (R&D) Limited

  公开号：US20150291602A1

  公开（公告）日：2015-10-15

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  本发明公开了化学式(I)的化合物，这些化合物能够作为嘌呤受体拮抗剂，并公开了包括这些化合物的制药组合物以及制备这些化合物的方法。这些化合物和组合物可用于治疗或预防与嘌呤受体过度功能相关的疾病。
• Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
  申请人：Vernalis (R&D) Limited

  公开号：US10106547B2

  公开（公告）日：2018-10-23

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  本发明公开了可作为嘌呤受体拮抗剂的式 (I) 化合物、包括该化合物的药物组合物以及制造该化合物的方法。这些化合物和组合物可用于治疗或预防与嘌呤受体功能亢进有关的疾病。
• Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
  申请人：Vernalis (R&D) Limited

  公开号：US10875868B2

  公开（公告）日：2020-12-29

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  本发明公开了能够作为嘌呤受体拮抗剂的式(I)化合物、包括该化合物的药物组合物以及制造该化合物的方法。这些化合物和组合物可用于治疗或预防与嘌呤受体功能亢进有关的疾病。